학술논문

Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
Document Type
Article
Source
In The Lancet Haematology February 2019 6(2):e100-e109
Subject
Primary Research
Articles
Language
ISSN
2352-3026